Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Go back to Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 254.63 -5.47 (2.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $260.10 | 52 Week High | $109.10 | |||
| Open | $257.07 | 52 Week Low | $31.38 | |||
| Day High | $261.98 | P/E | N/A | |||
| Day Low | $253.28 | EPS | $-1.45 | |||
| Volume | 840,511 | |||||
